Pharmacogenomics Market Projected to Reach $8.87 Billion by 2033 Amidst U.S. Labeling Changes
The global pharmacogenomics market is anticipated to grow significantly, with DataM Intelligence projecting a valuation of US$8.87 billion by 2033, up from US$4.31 billion in 2025. This represents a Compound Annual Growth Rate (CAGR) of 9.8% between 2026 and 2033. The growth is driven by advancements in genetic testing technologies and increasing adoption of personalized medicine. In the U.S., recent changes in FDA drug labeling and expanded test offerings are influencing the implementation of pharmacogenomics. For instance, the FDA updated its table of pharmacogenomic biomarkers in drug labeling in June 2026 and revised capecitabine and fluorouracil labeling in February 2026 to advise DPYD testing before treatment. North America is identified as the largest regional market, while Asia-Pacific is the fastest-growing. Key technologies contributing to this market include PCR, DNA sequencing, microarrays, electrophoresis, and mass spectrometry, alongside kits, reagents, instruments, software, and services.